Try our mobile app

Switch to company model in classical logic    *

General information

Country: CANADA

Sector: Drug Manufacturers — Specialty and Generic

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Website: bauschhealth.com



Growth: Pretty weak revenue growth rate 6.1%, there is slowdown compared to average historical growth rates 21.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +2.6%

Profitability: LTM EBITDA margin is positive, +21.9%. On average the margin is improving unsteadily. Gross margin is high, +71.1%. In the last quarter the company did not beat the estimated EPS, -27.8%. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.16 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 13.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 51.9% higher than minimum and 38.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 30.1% undervalued

Insiders: For the last 3 months insiders sold company shares on $0.3 mln (-0.010% of cap.)

Key Financials (Download financials)

Ticker: BHC
Share price, USD:  (0.0%)6.56
year average price 6.05  


year start price 7.21 2025-09-09

max close price 7.50 2026-01-13

min close price 4.43 2026-07-24

current price 6.56 2026-09-08
Common stocks: 362 239 735

Dividend Yield:  0.0%
FCF Yield LTM: 13.8%
EV / LTM EBITDA: 11.4x
EV / EBITDA annualized: 6.5x
Last revenue growth (y/y):  +6.1%
Last growth of EBITDA (y/y):  +27.3%
Historical revenue growth:  +21.3%
Historical growth of EBITDA:  +33.9%
EV / Sales: 2.5x
Margin (EBITDA LTM / Revenue): 21.9%
Fundamental value created in LTM:
Market Cap ($m): 2 376
Net Debt ($m): 21 392
EV (Enterprise Value): 23 768
Price to Book: -4.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-03fool.com

Overlooked and Undervalued: Why Bausch Health Companies Deserves Attention

2026-01-27zacks.com

BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down

2026-01-23reuters.com

Bausch Health's brain dysfunction treatment fails late-stage trial

2026-01-23prnewswire.com

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

2026-01-15seekingalpha.com

Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-29247wallst.com

2 Strong Mid-Cap Growth Stocks Dan Loeb Bought in Q3

2025-12-23accessnewswire.com

Bausch Health Announces Final Results and Expiration of Exchange Offers

2025-12-10fool.com

Bausch Health's Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake

2025-12-08accessnewswire.com

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

2025-12-02seekingalpha.com

Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-29 18:09:46 2025-07-30 18:36:32 2025-02-19 19:32:11 2024-10-30 19:13:33 2024-08-01 16:45:52 2024-05-02 16:57:48 2024-02-22 17:04:26 2023-11-02 16:58:48 2023-08-03 16:46:59 2023-05-04 16:41:21 2023-02-23 16:37:29 2022-11-03 16:50:45 2022-02-23 17:28:45 2021-02-24 17:13:18
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 912M 2 530M 9 625M 2 510M 2 403M 2 143M 8 757M 2 238M 2 167M 1 944M 8 124M 2 046M 8 434M 8 027M
costOfRevenue -668M 764M 2 782M 978M 989M 910M 2 559M 623M 649M 582M 2 364M 584M 2 394M 2 249M
grossProfit 1 580M 1 766M 6 843M 1 532M 1 414M 1 233M 6 198M 1 615M 1 518M 1 362M 5 760M 1 462M 6 040M 5 778M
grossProfitRatio 1.732 0.698 0.61 0.588 0.575 0.722 0.701 0.701 0.715
researchAndDevelopmentExpenses 166M 160M 634M 161M 156M 150M 604M 153M 156M 143M 530M 133M 473M 485M
generalAndAdministrativeExpenses 0 0 2 497M 0 0 0 2 270M 0 0 0 2 013M 0 1 977M 1 916M
sellingAndMarketingExpenses 0 0 786M 0 0 0 625M 0 0 0 518M 0 515M 451M
sellingGeneralAndAdministrativeExpenses 795M 894M 3 283M 850M 832M 790M 2 895M 715M 711M 725M 2 531M 661M 2 492M 2 367M
otherExpenses 0 268M 1 380M 0 -3M 0 1 736M -60M -1M 296M 2 245M 290M 2 625M 2 250M
operatingExpenses 961M 1 322M 5 297M 996M 988M 941M 5 235M 1 121M 1 053M 1 164M 5 306M 1 084M 5 590M 5 102M
costAndExpenses 293M 2 086M 8 079M 1 982M 1 977M 1 851M 7 794M 1 744M 1 702M 1 746M 7 670M 1 668M 7 984M 7 351M
interestIncome 15M 13M 33M 7M 8M 9M 26M 6M 7M 6M 14M 3M 7M 13M
interestExpense 2 002M 465M 1 388M 346M 350M 355M 1 328M 339M 319M 307M 1 464M 385M 1 426M 1 534M
depreciationAndAmortization 300M 307M 1 267M 325M 318M 319M 1 264M 253M 269M 302M 1 394M 335M 1 552M 1 825M
ebitda 2 520M 764M 3 134M 647M 719M 611M 2 885M 693M 741M 477M 2 878M 716M 3 260M 3 138M
ebitdaratio 2.763 0.302 0.258 0.31 0.285 0.31 0.342 0.245 0.35
operatingIncome 619M 444M 1 546M 318M 426M 293M 963M 14M 412M 175M 454M 381M 450M 676M
operatingIncomeRatio 0.679 0.175 0.127 0.177 0.137 0.006 0.19 0.09 0.186
totalOtherIncomeExpensesNet -401M -304M -1 379M -339M -341M -361M -1 353M -487M -74M -311M -583M 58M -1 474M -1 610M
incomeBeforeTax 218M 140M 167M -21M 48M -69M -390M -326M 79M -136M -129M 439M -1 024M -934M
incomeBeforeTaxRatio 0.239 0.055 -0.008 0.02 -0.032 -0.146 0.036 -0.07 0.215
incomeTaxExpense 39M 12M 239M 72M 49M 8M 221M 56M 52M 73M 83M 36M -87M -375M
netIncome 179M 148M -46M -85M 10M -64M -592M -378M 26M -209M -225M 399M -948M -559M
netIncomeRatio 0.196 0.058 -0.034 0.004 -0.03 -0.169 0.012 -0.108 0.195
eps -0.24 0.4 -0.13 -0.23 0.027 -0.17 -1.62 -1.03 0.07 -0.58 -0.59 1.1 -2.61 -1.57
epsdiluted -0.24 0.4 -0.23 0.027 -0.17 -1.03 0.07 -0.58 1.1
weightedAverageShsOut 371M 371M 368M 368M 368M 367M 365M 365M 371M 363M 362M 363M 359M 355M
weightedAverageShsOutDil 373M 373M 368M 368M 370M 367M 365M 365M 371M 363M 362M 363M 359M 355M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -1 355M -1 302M -1 450M -1 419M -1 521M
ebit 1 867M 1 621M 1 484M 1 708M 1 313M
nonOperatingIncomeExcludingInterest -321M -658M -1 030M -1 258M -637M
netIncomeFromContinuingOperations -72M -611M -212M -937M -559M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -46M -592M -225M -948M -560M
epsDiluted -0.13 -1.62 -0.59 -2.61 -1.57

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-29 18:09:46 2025-07-30 18:36:32 2025-02-19 19:32:11 2024-10-30 19:13:33 2024-08-01 16:45:52 2024-05-02 16:57:48 2024-02-22 17:04:26 2023-11-02 16:58:48 2023-08-03 16:46:59 2023-05-04 16:41:21 2023-02-23 16:37:29 2022-11-03 16:50:45 2022-02-23 17:28:45 2021-02-24 17:13:18
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 339M 1 727M 1 181M 719M 623M 754M 947M 760M 767M 518M 564M 486M 582M 605M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 1 339M 1 727M 1 181M 719M 623M 754M 947M 760M 767M 518M 564M 486M 582M 605M
netReceivables 2 415M 2 210M 2 140M 2 094M 2 102M 2 046M 1 998M 1 948M 2 310M 1 688M 1 790M 1 739M 1 775M 1 577M
inventory 1 596M 1 655M 1 595M 1 655M 1 612M 1 634M 1 544M 1 272M 1 643M 1 222M 1 090M 1 056M 993M 1 094M
otherCurrentAssets 893M 922M 858M 883M 902M 956M 1 107M 1 048M 1 179M 796M 39M 718M 1 538M 1 223M
totalCurrentAssets 6 243M 6 514M 5 774M 5 351M 5 210M 5 390M 5 596M 5 048M 5 912M 4 237M 4 247M 4 010M 5 607M 5 342M
propertyPlantEquipmentNet 2 024M 1 994M 1 780M 1 789M 1 738M 1 711M 1 707M 1 584M 2 119M 1 596M 1 600M 1 507M 1 598M 1 567M
goodwill 11 276M 11 298M 11 087M 11 171M 11 125M 11 148M 11 183M 11 187M 15 410M 11 579M 11 547M 12 044M 12 457M 13 044M
intangibleAssets 4 825M 5 047M 5 551M 5 652M 5 903M 6 183M 6 456M 6 728M 7 022M 5 552M 5 800M 6 024M 6 948M 8 445M
goodwillAndIntangibleAssets 16 101M 16 345M 16 638M 16 823M 17 030M 17 343M 17 639M 17 915M 22 432M 17 131M 17 347M 18 068M 19 405M 21 489M
longTermInvestments 0 0 0 0 -2M -18M 0 0 0 0 0 0 0 0
taxAssets 2 048M 2 025M 1 968M 2 188M 2 187M 2 147M 2 101M 2 189M 2 904M 2 163M 2 166M 2 372M 2 252M 2 137M
otherNonCurrentAssets 382M 388M 363M 389M 329M 312M 307M 328M 431M 318M 326M 341M 340M 664M
totalNonCurrentAssets 20 555M 20 752M 20 749M 21 189M 21 281M 21 495M 21 754M 22 016M 27 885M 21 208M 21 439M 22 288M 23 595M 25 857M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0 0
totalAssets 26 798M 27 266M 26 523M 26 540M 26 491M 26 885M 27 350M 27 064M 33 797M 25 445M 25 686M 26 298M 29 202M 31 199M
accountPayables 615M 627M 656M 667M 579M 641M 719M 569M 682M 561M 521M 486M 407M 337M
shortTermDebt 578M 879M 2 674M 453M 452M 537M 450M 536M 588M 446M 432M 411M 0 0
taxPayables 0 0 63M 102M 78M 76M 47M 70M 69M 46M 30M 66M 98M 158M
deferredRevenue 0 0 0 0 78M 76M 0 2 771M 2 531M 0 0 0 0 0
otherCurrentLiabilities 3 594M 3 469M 1 327M 3 284M 3 260M 3 146M 1 401M 348M 1 455M 2 916M 1 340M 2 934M 2 975M 2 755M
totalCurrentLiabilities 4 788M 4 975M 6 752M 4 506M 4 368M 4 400M 4 302M 4 224M 5 257M 3 923M 3 941M 3 831M 5 198M 4 913M
longTermDebt 20 443M 20 859M 18 942M 21 054M 21 208M 21 514M 21 938M 21 894M 26 647M 20 207M 20 334M 20 804M 22 654M 23 925M
deferredRevenueNonCurrent 0 0 0 0 1 1 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 145M 144M 128M 169M 170M 170M 163M 213M 285M 205M 202M 422M 529M 528M
otherNonCurrentLiabilities 1 066M 1 141M 857M 1 053M 1 145M 975M 1 029M 968M 1 248M 965M 949M 21 137M 855M 1 228M
totalNonCurrentLiabilities 21 654M 22 144M 20 093M 22 276M 22 350M 22 659M 23 130M 23 075M 28 181M 21 377M 21 485M 22 034M 24 038M 25 681M
otherLiabilities 0 0 0 0 1 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 223M 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 26 442M 27 119M 26 845M 26 782M 26 718M 27 059M 27 432M 27 299M 33 438M 25 300M 25 426M 25 865M 29 236M 30 594M
preferredStock 0 0 0 0 0 0 0 0 61M 0 0 0 0 0
commonStock 10 505M 10 510M 10 490M 10 489M 10 481M 10 469M 10 423M 10 420M 13 798M 10 405M 10 391M 10 387M 10 317M 10 227M
retainedEarnings -9 546M -9 734M -9 824M -9 917M -9 831M -9 832M -9 778M -9 739M -12 405M -9 387M -9 186M -8 776M -8 961M -8 013M
accumulatedOtherComprehensiveIncomeLoss -1 798M -1 790M -2 179M -1 947M -2 007M -1 915M -1 881M -2 051M -2 521M -1 989M -2 056M -2 265M -1 924M -2 133M
othertotalStockholdersEquity 275M 250M 201M 181M 164M 190M 188M 171M 129M
totalStockholdersEquity -564M -764M -1 279M -1 174M -1 175M -1 114M -1 022M -1 180M -879M -800M -692M -525M -106M 535M
totalEquity 356M 147M -322M -242M -227M -174M -82M -235M 359M -800M 260M -525M -34M 605M
totalLiabilitiesAndStockholdersEquity 26 798M 27 266M 26 540M 26 491M 26 885M 27 064M 33 797M 25 445M 26 298M
minorityInterest 920M 911M 957M 932M 948M 940M 940M 945M 1 238M 945M 952M 0 72M 70M
totalLiabilitiesAndTotalEquity 26 798M 27 266M 26 523M 26 540M 26 491M 26 885M 27 350M 27 064M 33 797M 25 445M 25 686M 26 298M 29 202M 31 199M
totalInvestments 0 0 0 0 -2M -18M 0 0 0 0 0 0 0 0
totalDebt 21 021M 21 738M 21 826M 21 507M 21 657M 22 051M 22 388M 22 430M 27 236M 20 653M 20 766M 21 215M 22 654M 23 925M
netDebt 19 683M 20 011M 20 626M 20 788M 21 034M 21 297M 21 441M 21 670M 26 468M 20 135M 20 202M 20 729M 22 072M 23 320M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2 140M 1 998M 1 790M 1 775M 1 577M
otherReceivables 0 0 0 0 0
prepaids 0 0 764M 719M 843M
totalPayables 719M 766M 551M 505M 495M
otherPayables 63M 47M 30M 98M 158M
accruedExpenses 1 974M 1 685M 1 618M 1 718M 1 663M
capitalLeaseObligationsCurrent 58M 0 0 0 0
capitalLeaseObligationsNonCurrent 165M 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 234M 214M 159M 462M 454M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC BHC
reportedCurrency USD USD USD USD USD USD USD USD CAD USD USD USD USD USD
cik 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590 885 590
fillingDate 2025-10-30 2025-07-31 2024-10-31 2024-08-01 2024-05-02 2023-11-02 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-10-29 18:09:46 2025-07-30 18:36:32 2025-02-19 19:32:11 2024-10-30 19:13:33 2024-08-01 16:45:52 2024-05-02 16:57:48 2024-02-22 17:04:26 2023-11-02 16:58:48 2023-08-03 16:46:59 2023-05-04 16:41:21 2023-02-23 16:37:29 2022-11-03 16:50:45 2022-02-23 17:28:45 2021-02-24 17:13:18
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 181M 128M -72M -92M 10M -64M -611M -382M 42M -209M -212M 403M -937M -559M
depreciationAndAmortization 306M 307M 1 267M 322M 318M 319M 1 264M 301M 409M 319M 1 394M 335M 1 552M 1 825M
deferredIncomeTax -24M -42M 66M -3M -44M -57M 51M -3M -40M 0 -176M -96M -225M -475M
stockBasedCompensation 43M 46M 150M 38M 36M 33M 132M 29M 43M 41M 126M 33M 128M 105M
changeInWorkingCapital -53M -72M 7M 126M 32M -35M -582M -148M -267M -61M -396M -269M -128M -366M
accountsReceivables -218M -91M -216M 178M -72M -63M -195M -231M -73M 108M -57M -133M -229M 170M
inventory 16M 7M -267M -42M -33M -143M -322M -62M -39M -128M -198M -56M -16M -77M
accountsPayables 0 0 357M 145M 137M 51M 158M 165M 0 -8M -75M -96M 121M -471M
otherWorkingCapital 149M 12M 133M -155M -1M 120M -223M -20M -155M -33M -66M 16M -4M 12M
otherNonCashItems -48M -78M 179M 20M 667M 835M 778M 485M 83M 64M -1 464M -1 669M 1 036M 581M
netCashProvidedByOperatingActivities 405M 289M 1 597M 411M 379M 206M 1 032M 282M 269M 154M -728M -1 263M 1 426M 1 111M
investmentsInPropertyPlantAndEquipment -91M -99M -337M -69M -79M -83M -215M -46M -40M -51M -218M -59M -269M -302M
acquisitionsNet -5M 0 0 -40M 1M 995 533 -1 890M -1 856M 849 090 -31M -45M 0 0 0
purchasesOfInvestments -1 000 000 -1 000 000 -12M -2M -2M -3M -27M -2M 3M -13M -17M -1 000 000 -19M -4M
salesMaturitiesOfInvestments 1 000 000 1 000 000 14M 4M 1M 6M 26M 4M -3M 11M 22M 7M 15M 8M
otherInvestingActivites 13M -1 000 000 6M 43 799 6M 11M 1M 6M 0
netCashUsedForInvestingActivites -83M -100M -102M -79M -73M -1 889M -38M -78M -53M
debtRepayment -705M 405M -164M -414M -314M -817M -537M -279M -141M
commonStockIssued 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 -3M -26M 18M -4M -14M 0 -8M 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -14M -44M -25M -9M -21M 2 641M 382M 137M 105M
netCashUsedProvidedByFinancingActivities -719M 358M -189M -423M -334M 1 816M -155M -142M -36M
effectOfForexChangesOnCash -6M 39M -36M 13M -9M -5M 9M -17M 1M 6M -23M -30M -19M 16M
netChangeInCash -403M 586M 239M 127M -131M -203M 371M 192M 61M -60M -1 528M -1 382M 303M -1 428M
cashAtEndOfPeriod 1 340M 1 743M 1 201M 750M 623M 754M 962M 780M 779M 531M 591M 497M 2 119M 1 816M
cashAtBeginningOfPeriod 1 743M 1 157M 962M 623M 754M 957M 591M 588M 718M 591M 2 119M 1 879M 1 816M 3 244M
operatingCashFlow 405M 289M 1 597M 411M 379M 206M 1 032M 282M 269M 154M -728M -1 263M 1 426M 1 111M
capitalExpenditure -91M -99M -337M -69M -79M -83M -272M -46M -40M -51M -268M -59M -283M -309M
freeCashFlow 314M 190M 1 260M 342M 300M 123M 760M 236M 229M 103M -996M -1 322M 1 143M 802M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-02-23 2022-02-23 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -119M -39M -45M 682M 37M
netCashProvidedByInvestingActivities -454M -2 145M -303M 409M -261M
netDebtIssuance -799M 1 581M -1 010M -1 340M -2 187M
longTermNetDebtIssuance -799M 1 581M -1 010M -1 340M -2 187M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -26M 0 675M 0 0
netCommonStockIssuance -26M 0 675M 0 0
commonStockIssuance 0 0 675M 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -43M -106M -139M -173M -107M
netCashProvidedByFinancingActivities -868M 1 475M -474M -1 513M -2 294M
incomeTaxesPaid 61M 237M 266M 0 0
interestPaid 1 674M 1 533M 1 540M 0 0

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-19 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-28 20:15 ET
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
2026-05-19 20:15 ET
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
2026-05-13 ET
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
2026-05-12 ET
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
2026-04-29 ET
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
2026-04-14 ET
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
2026-03-31 ET
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
2026-03-26 ET
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
2026-02-23 ET
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
2026-02-19 ET
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
2026-02-18 ET
BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
2026-02-17 12:00 ET
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
2026-02-11 13:00 ET
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
2026-01-23 ET
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
2026-01-21 ET
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
2026-01-05 ET
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-23 ET
Bausch Health Announces Final Results and Expiration of Exchange Offers
2025-12-08 ET
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
2025-12-01 ET
Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China
2025-11-24 ET
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
2025-11-18 ET
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-05 ET
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
2025-10-29 ET
Bausch Health Announces Third Quarter 2025 Results
2025-10-09 ET
Bausch Health Announces Results of Special Meeting of Shareholders
2025-09-30 ET
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
2025-09-30 ET
Bausch Health to Announce Third Quarter 2025 Results on October 29
2025-09-29 ET
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
2025-09-11 ET
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
2025-09-11 ET
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
2025-09-05 ET
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
2025-08-26 ET
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
2025-08-21 ET
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
2025-08-15 ET
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
2025-08-07 ET
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
2025-07-30 ET
Bausch Health Announces Second Quarter 2025 Results
2025-07-29 ET
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
2025-07-29 ET
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
2025-07-28 ET
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
2025-07-24 ET
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
2025-07-10 ET
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
2025-07-10 ET
Bausch Health Appoints New Chief Accounting Officer
2025-07-09 ET
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
2025-07-07 ET
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
2025-07-02 ET
Bausch Health to Announce Second Quarter 2025 Results on July 30
2025-05-14 ET
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
2025-05-06 ET
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
2025-04-30 ET
Bausch Health Announces First Quarter 2025 Results
2025-04-29 ET
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
2025-04-25 ET
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)
2025-04-22 ET
Bausch Health Announces Filing of Supplement to Proxy Statement
2025-04-17 ET
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
2025-04-14 ET
Bausch Health Announces Adoption of Shareholder Rights Plan
2025-04-10 ET
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
2025-04-09 ET
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
2025-04-02 ET
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
2025-03-27 ET
Bausch Health to Announce First Quarter Results on April 30
2025-03-25 ET
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
2025-03-21 ET
Bausch Health Announces Conditional Redemption of Senior Notes
2025-03-19 ET
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
2025-03-19 ET
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
2025-03-14 ET
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
2025-02-19 ET
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
2025-02-14 ET
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
2025-02-10 ET
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
2025-02-06 ET
Bausch Health Provides Update on Strategic Alternatives
2025-01-23 ET
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
2025-01-17 ET
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
2024-12-12 ET
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
2024-12-05 ET
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
2024-12-02 ET
Bausch Health Appoints New Chief Medical Officer and Head of R&D
2024-11-18 ET
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
2024-11-18 ET
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
2024-10-30 20:05 ET
Bausch Health Announces Third Quarter 2024 Results
2024-10-27 16:15 ET
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
2024-10-09 20:05 ET
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
2024-10-08 12:00 ET
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
2024-09-11 11:00 ET
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
2024-08-13 11:00 ET
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
2024-07-31 04:00 ET
Bausch Health Announces Second Quarter 2024 Results
2024-07-24 16:50 ET
Bausch Health Responds to Market Rumors
2024-07-19 11:00 ET
Bausch Health Welcomes Two New Members to the Executive Leadership Team
2024-07-11 11:00 ET
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
2024-06-20 21:28 ET
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
2024-06-14 18:30 ET
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
2024-05-23 12:00 ET
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
2024-05-17 12:00 ET
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
2024-05-15 12:00 ET
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
2024-05-14 20:21 ET
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
2024-05-09 12:00 ET
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
2024-05-02 11:00 ET
Bausch Health Announces First Quarter 2024 Results
2024-04-11 20:22 ET
Bausch Health to Announce First-Quarter 2024 Results on May 2
2024-04-11 17:03 ET
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
2024-04-11 12:00 ET
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
2024-04-05 22:15 ET
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
2024-04-03 12:00 ET
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
2024-04-02 12:00 ET
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
2024-03-06 13:00 ET
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
2024-03-05 13:00 ET
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
2024-03-01 13:00 ET
Bausch Health Companies to Present at Cowen Annual Health Care Conference
2024-02-22 12:00 ET
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
2024-02-12 13:00 ET
Salix Announces 2024 Gastrointestinal Health Scholars Program
2024-02-01 21:10 ET
Bausch Health Announces Board Refreshment
2024-02-01 13:00 ET
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
2024-01-30 13:00 ET
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
2024-01-18 21:50 ET
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
2024-01-18 13:00 ET
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
2024-01-18 ET
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
2024-01-08 05:00 ET
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
2023-12-21 12:00 ET
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
2023-12-18 13:00 ET
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
2023-12-05 13:00 ET
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
2023-11-10 13:00 ET
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
2023-11-08 13:00 ET
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
2023-11-02 11:00 ET
Bausch Health Announces Third-Quarter 2023 Results
2023-11-01 16:22 ET
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
2023-10-26 12:00 ET
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
2023-10-20 21:20 ET
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
2023-10-17 12:00 ET
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
2023-10-12 12:00 ET
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
2023-10-10 12:00 ET
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
2023-10-04 12:00 ET
Salix Pharmaceuticals Partners with Bellamy Young
2023-09-29 14:15 ET
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
2023-09-21 12:00 ET
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
2023-09-18 21:45 ET
Bausch Health Announces CFO Transition Plan
2023-09-12 12:00 ET
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
2023-09-11 12:00 ET
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
2023-09-06 22:16 ET
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)
2023-08-03 11:00 ET
Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook
2023-07-27 12:00 ET
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
2023-07-13 12:00 ET
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
2023-07-11 12:00 ET
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
2023-07-07 12:00 ET
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
2023-07-07 11:00 ET
Bausch Health Enters Into $600 Million Financing Facility With KKR
2023-06-30 12:30 ET
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
2023-06-19 12:00 ET
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
2023-06-06 12:00 ET
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
2023-05-31 12:00 ET
OraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum Disease
2023-05-18 12:00 ET
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
2023-05-17 17:20 ET
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
2023-05-17 12:00 ET
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
2023-05-10 12:00 ET
Bausch Health Observes Mental Health Awareness Month
2023-05-08 12:00 ET
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
2023-05-04 11:00 ET
Bausch Health Announces First-Quarter 2023 Results
2023-05-01 12:00 ET
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
2023-04-24 12:00 ET
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
2023-04-13 12:00 ET
Bausch Health to Announce First-Quarter 2023 Results on May 4
2023-04-04 15:15 ET
Court Upholds Fraudulent Conveyance Claims against Bausch Health, Including Right to Enjoin Dividend of Bausch + Lomb Shares
2023-04-04 12:00 ET
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
2023-03-01 13:00 ET
Bausch Health Announces Changes to its Board of Directors
2023-02-23 12:00 ET
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
2023-02-13 13:00 ET
Salix Announces 2023 Gastrointestinal Health Scholars Program
2023-02-01 13:00 ET
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
2022-12-14 13:35 ET
Judge Finds Bausch Health Spin-Off Not “Imminent;” Orders Bausch Health to Provide Advance Notice of Intent to Spin in Order to Allow Injunction Challenge
2022-12-02 13:00 ET
Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case
2022-12-01 13:00 ET
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
2022-11-30 15:45 ET
RKS WINS MAJOR RULING: FRAUDULENT TRANSFER CLAIMS AGAINST BAUSCH HEALTH, BAUSCH + LOMB WILL MOVE FORWARD
2022-11-29 22:50 ET
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
2022-11-04 12:00 ET
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
2022-11-03 11:00 ET
Bausch Health Announces Third-Quarter 2022 Results
2022-11-01 12:00 ET
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
2022-10-31 12:00 ET
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
2022-10-24 12:00 ET
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
2022-10-20 12:00 ET
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
2022-10-13 12:00 ET
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
2022-10-12 12:00 ET
SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION
2022-10-05 12:00 ET
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
2022-10-03 12:00 ET
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY
2022-09-28 12:09 ET
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
2022-09-15 20:05 ET
Kimball Electronics, Inc. Announces Appointment of Additional Director
2022-09-14 13:00 ET
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
2022-09-09 11:00 ET
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
2022-09-08 20:45 ET
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
2022-08-31 03:28 ET
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
2022-08-22 11:00 ET
Bausch Health Continuing Process Toward Separating Bausch + Lomb
2022-08-10 22:00 ET
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
2022-08-10 11:00 ET
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
2022-08-09 11:00 ET
BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS
2022-07-28 19:45 ET
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
2022-07-27 23:35 ET
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
2022-07-20 11:00 ET
Bausch + Lomb Provides Leadership Update
2022-07-13 11:00 ET
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
2022-06-23 20:54 ET
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
2022-06-21 11:00 ET
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
2022-06-20 11:00 ET
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
2022-06-16 21:30 ET
Bausch Health Provides Update on Solta Medical
2022-05-18 11:00 ET
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
2022-05-11 11:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2022-05-10 16:46 ET
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
2022-05-10 10:59 ET
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
2022-05-06 16:08 ET
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
2022-05-05 23:50 ET
Bausch + Lomb Corporation Announces Pricing of IPO
2022-05-03 10:59 ET
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
2022-04-29 11:00 ET
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
2022-04-28 13:43 ET
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
2022-04-28 13:40 ET
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
2022-04-28 10:50 ET
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
2022-04-27 20:32 ET
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
2022-04-25 10:59 ET
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
2022-04-21 10:59 ET
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
2022-04-20 11:00 ET
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
2022-04-18 10:59 ET
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
2022-04-07 12:06 ET
SALIX PHARMACEUTICALS WILL PRESENT SCIENTIFIC DATA AT THE SOCIETY OF HOSPITAL MEDICINE CONVERGE 2022
2022-04-04 10:30 ET
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
2022-03-29 18:45 ET
Major Investors Sue to Void Over $3 Billion of Bausch + Lomb Spin-Off
2022-03-29 11:00 ET
Bausch Health Will Reduce Debt By $200 Million
2022-03-24 11:00 ET
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
2022-03-22 20:05 ET
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
2022-03-22 10:59 ET
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
2022-03-03 12:00 ET
Bausch Health Announces Participation in Upcoming Investor Conferences
2022-03-02 11:59 ET
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
2022-03-01 12:00 ET
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
2022-02-24 12:00 ET
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
2022-02-23 11:59 ET
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
2022-02-22 11:59 ET
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
2022-02-15 12:00 ET
Salix Announces 2022 Gastrointestinal Health Scholars Program
2022-02-08 21:55 ET
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering
2022-02-03 12:00 ET
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23
2022-02-01 11:59 ET
BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS
2022-01-27 21:21 ET
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
2022-01-27 13:09 ET
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
2022-01-20 12:00 ET
Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
2022-01-18 12:48 ET
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
2022-01-13 21:27 ET
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering
2022-01-11 12:00 ET
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference
2022-01-05 12:00 ET
BAUSCH HEALTH TO PARTICIPATE AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2022-01-04 11:59 ET
NEW SURVEY FROM BAUSCH + LOMB AND GLAUCOMA RESEARCH FOUNDATION REVEALS EMOTIONAL AND SOCIAL IMPACT OF HYPEREMIA ON GLAUCOMA PATIENTS
2021-12-22 12:00 ET
RELISTOR® (METHYLNALTREXONE BROMIDE) DATA IS PUBLISHED IN THE JOURNAL OF EMERGENCY MEDICINE
2021-12-06 11:59 ET
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
2021-12-03 12:00 ET
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
2021-11-15 11:59 ET
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
2021-11-11 12:00 ET
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
2021-11-04 11:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2021-11-02 10:59 ET
Bausch Health Companies Inc. Announces Third-Quarter 2021 Results
2021-11-01 11:00 ET
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
2021-10-27 10:59 ET
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
2021-10-25 12:00 ET
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
2021-10-25 11:00 ET
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
2021-10-21 11:00 ET
Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer
2021-10-19 11:00 ET
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference
2021-10-07 09:51 ET
Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience
2021-10-06 11:00 ET
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2
2021-09-30 10:59 ET
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
2021-09-29 11:00 ET
Bausch Health Releases Annual Environmental, Social and Governance Report
2021-09-02 11:00 ET
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
2021-09-01 11:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2021-08-03 10:59 ET
Bausch Health Companies Inc. Announces Second-Quarter 2021 Results
2021-08-03 10:57 ET
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical
2021-08-03 10:45 ET
Bausch Health To Reduce Debt By $350 Million
2021-08-02 11:00 ET
Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ
2021-07-29 11:00 ET
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients
2021-07-22 11:00 ET
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners
2021-07-19 10:59 ET
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery
2021-07-12 10:59 ET
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
2021-07-07 10:59 ET
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)
2021-07-06 11:00 ET
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3
2021-07-01 11:00 ET
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
2021-06-23 11:00 ET
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
2021-06-22 11:00 ET
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021
2021-06-21 11:00 ET
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors
2021-06-08 10:59 ET
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
2021-06-07 22:46 ET
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes
2021-06-01 10:59 ET
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
2021-05-27 11:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2021-05-25 11:00 ET
Bausch Health Announces Participation At The Jefferies Healthcare Conference
2021-05-24 21:30 ET
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
2021-05-24 12:21 ET
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024
2021-05-24 12:20 ET
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes
2021-05-17 11:00 ET
Salix Will Feature New Data At Digestive Disease Week® 2021
2021-05-11 10:59 ET
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
2021-05-06 11:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2021-05-04 10:59 ET
Bausch Health Companies Inc. Announces First-Quarter 2021 Results
2021-05-03 11:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2021-04-29 10:59 ET
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
2021-04-28 11:00 ET
Bausch Health Announces 2021 Annual Meeting of Shareholder Results
2021-04-27 11:00 ET
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation
2021-04-22 10:59 ET
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
2021-04-21 10:59 ET
Ortho Dermatologics to Present New Data at the 2021 American Academy of Dermatology Annual Meeting
2021-04-16 11:00 ET
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
2021-04-15 11:00 ET
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
2021-04-13 10:58 ET
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
2021-04-09 11:00 ET
Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4
2021-04-08 11:00 ET
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement
2021-04-07 11:30 ET
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
2021-04-07 11:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2021-03-31 12:00 ET
Bausch Health Agrees To Sell Amoun Pharmaceuticals
2021-03-30 13:00 ET
Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE
2021-03-11 12:00 ET
Bausch Health Announces CFO Succession Plan
2021-03-09 12:00 ET
Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
2021-03-08 11:58 ET
Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser
2021-02-26 12:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2021-02-24 11:59 ET
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
2021-02-24 11:45 ET
Bausch Health Announces Agreement With Carl C. Icahn
2021-02-23 12:00 ET
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
2021-02-22 12:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2021-02-18 13:30 ET
Salix Announces 2021 Gastrointestinal Health Scholars Program
2021-02-16 12:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2021-02-12 02:26 ET
Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP
2021-02-09 12:00 ET
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
2021-02-02 12:00 ET
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program
2021-02-01 12:00 ET
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
2021-01-27 12:00 ET
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24
2021-01-21 12:00 ET
South Korea's MFDS Approves LUMIFY® Eye Drops
2021-01-20 12:00 ET
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
2021-01-19 12:00 ET
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)
2021-01-12 21:15 ET
Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery
2021-01-06 12:00 ET
Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference
2020-12-30 12:00 ET
Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)
2020-12-29 12:00 ET
Bausch Health To Reduce Debt By $275 Million
2020-11-24 12:00 ET
Bausch Health Initiates Second Phase 3 Study For NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunction
2020-11-18 21:51 ET
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Conditional Redemption Of Additional Series Of Existing Senior Notes
2020-11-18 12:08 ET
Bausch Health Announces Launch Of Private Offering Of Senior Notes And Conditional Redemption Of Existing Senior Notes
2020-11-16 12:00 ET
Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride
2020-11-12 11:59 ET
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through One By One Recycling Program
2020-11-11 12:00 ET
Salix To Present Data At AASLD's The Liver Meeting Digital Experience
2020-11-10 12:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2020-11-03 11:59 ET
Bausch Health Companies Inc. Announces Third-Quarter 2020 Results
2020-10-29 20:05 ET
Bausch Health's Rifaximin Receives FDA Orphan Designation For Sickle Cell Disease
2020-10-29 11:00 ET
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
2020-10-27 10:58 ET
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses
2020-10-26 10:58 ET
Ortho Dermatologics To Present New Analyses At The Virtual Fall Clinical Dermatology Conference
2020-10-22 11:00 ET
Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting
2020-10-15 11:00 ET
Bausch Health And BHVI Announce Exclusive Global Licensing Agreement For Myopia Control Contact Lens
2020-10-13 11:00 ET
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
2020-10-12 11:00 ET
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12
2020-10-08 12:00 ET
Salix To Present Clinical Data At United European Gastroenterology Week Virtual 2020
2020-10-08 11:00 ET
Bausch Health Companies Inc. Provides Preliminary Update On Third-Quarter 2020 Financial Results And Business Recovery
2020-10-06 11:00 ET
Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented On Bausch + Lomb Infuse™ Silicone Hydrogel Daily Disposable Contact Lenses During The American Academy Of Optometry Annual Meeting
2020-10-05 11:00 ET
Salix Supports Liver Awareness Month With New Educational Initiatives
2020-10-01 11:00 ET
Nielsen's BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
2020-09-24 10:55 ET
Bausch Health Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved In Seven Countries
2020-09-23 11:00 ET
Bausch Health Releases Annual Corporate Social Responsibility Report
2020-09-22 11:00 ET
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
2020-09-21 11:00 ET
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics
2020-09-16 11:00 ET
Bausch Health Provides Company Update At 18th Annual Morgan Stanley Global Healthcare Conference
2020-09-10 11:00 ET
Bausch Foundation Releases Inaugural Activity Report
2020-09-09 11:00 ET
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference
2020-09-03 11:05 ET
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
2020-08-31 11:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2020-08-18 11:00 ET
Australia's TGA Approves BAUSCH + LOMB ULTRA® ONE DAY Silicone Hydrogel Daily Disposable Contact Lenses
2020-08-17 11:00 ET
Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (SiHy) Daily Disposable Contact Lenses
2020-08-11 11:00 ET
Health Canada Approves BAUSCH + LOMB ULTRA ONE DAY® Silicone Hydrogel Daily Disposable Contact Lenses
2020-08-06 10:59 ET
Bausch Health Companies Inc. Announces Second-Quarter 2020 Results
2020-08-06 10:59 ET
Bausch Health Announces Its Intention To Spin Off Its Eye Health Business Into An Independent Publicly Traded Company
2020-08-05 11:00 ET
Bausch Health Resolves Canadian Securities Class Action
2020-07-31 20:43 ET
Bausch Health Resolves Legacy SEC Investigation
2020-07-28 11:00 ET
Ortho Dermatologics Announces 2020 Aspire Higher Scholarship Recipients
2020-07-23 11:00 ET
Bausch Health Companies Inc. Will Release Second-Quarter 2020 Financial Results On August 6
2020-06-23 11:00 ET
Ortho Dermatologics Launches ARAZLO™ (tazarotene) Lotion, 0.045%, In The United States
2020-06-17 20:15 ET
BAUSCH + LOMB ULTRA® Silicone Hydrogel Contact Lenses Receive Approval In China
2020-06-16 11:00 ET
Bausch Health to Participate at Goldman Sachs Annual Leveraged Finance Conference
2020-06-15 11:00 ET
Salix Announces Inaugural Salix Gastrointestinal Health Scholars Program Recipients
2020-06-04 11:00 ET
FDA Provides 510(k) Clearance For BAUSCH + LOMB INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses
2020-05-27 11:00 ET
Bausch + Lomb Announces The European Launch Of LuxSmart™ And LuxGood™ Preloaded Intraocular Lenses
2020-05-21 11:00 ET
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference
2020-05-11 20:20 ET
Bausch Health Announces Pricing And Upsize Of Private Offering Of Senior Notes And Prepayment Of Term Loan 2022 Mandatory Amortization
2020-05-11 11:09 ET
Bausch Health Announces Launch of Private Offering of Senior Notes and Conditional Redemption of Existing Senior Secured Notes
2020-05-07 10:59 ET
Bausch Health Companies Inc. Announces First-Quarter 2020 Results
2020-05-06 11:00 ET
Bausch Health And Alfasigma Announce Resolution Of XIFAXAN® Intellectual Property Litigation
2020-04-30 11:00 ET
Bausch Health To Participate at 2020 Bank of America Merrill Lynch Global Healthcare Conference
2020-04-30 10:45 ET
Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting
2020-04-29 20:50 ET
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results
2020-04-29 11:00 ET
FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old
2020-04-28 11:00 ET
Bausch Health Issues Form 8-K For 2020 Annual Meeting Of Shareholders Presentation
2020-04-23 11:00 ET
Bausch Health Companies Inc. Will Release First-Quarter 2020 Financial Results On May 7
2020-04-14 12:00 ET
Bausch + Lomb Announces Publication Of 10-Year Armor Study Results On Ocular Antibiotic Resistance In JAMA Ophthalmology
2020-04-13 11:00 ET
Bausch Health Initiates VIRAZOLE® (Ribavirin for Inhalation Solution, USP) Clinical Study in Patients with COVID-19
2020-04-02 20:30 ET
Bausch Health Companies Inc. Will Hold Virtual Annual Meeting Of Shareholders On April 28
2020-03-31 11:00 ET
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
2020-03-24 16:32 ET
Bausch Health Donates Health Care Products And Supplies Through Bausch Foundation In Response To COVID-19 Pandemic
2020-03-13 11:00 ET
Bausch Health To Reduce Debt By Approximately $100 Million Using Cash Generated From Operations
2020-03-02 23:00 ET
Bausch Health Announces It Will No Longer Pursue Proposed Refinancing Transaction And Also Announces Cancellation Of Previously Delivered Notice Of Conditional Redemption
2020-02-19 21:40 ET
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes
2020-02-19 11:59 ET
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2019 Results And Provides 2020 Guidance
2020-02-18 12:00 ET
Ortho Dermatologics Launches Telemedicine on Dermatology.com, U.S. Cash-Pay Prescription Program
2020-02-12 12:00 ET
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
2020-02-04 12:00 ET
Bausch Health Announces Participation In Upcoming Investor Conferences
2020-02-03 13:00 ET
Bausch + Lomb And Prevent Blindness Join Together To Raise Awareness And Provide Educational Resources For February's Age-Related Macular Degeneration Awareness Month
2020-02-03 12:00 ET
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program
2020-01-16 12:00 ET
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2019 Financial Results on February 19
2020-01-13 12:00 ET
Bausch Health Publishes Company Update for the 38th Annual J.P. Morgan Healthcare Conference
2020-01-13 11:45 ET
Ortho Dermatologics Announces Publication Of Pivotal Phase 3 Data On ARAZLO(TM) (tazarotene) Lotion, 0.045% In The Journal Of Drugs In Dermatology (JDD)
2020-01-06 13:28 ET
Bausch + Lomb Launches Expanded Parameters for Biotrue® ONEday for Astigmatism Daily Disposable Contact Lenses
2020-01-06 12:00 ET
Bausch Health To Participate At The 38th Annual J.P. Morgan Healthcare Conference
2019-12-20 11:45 ET
Bausch Health Announces Resolution Of BRYHALI® (Halobetasol Propionate) Lotion, 0.01%, Intellectual Property Litigation With Glenmark
2019-12-17 13:28 ET
Bausch + Lomb Initiates Clinical Trial Evaluating New Cohesive Ophthalmic Viscosurgical Device (OVD) For Use In Cataract Surgery
2019-12-17 12:15 ET
Bausch Health Announces Launch Of Private Offering Of Senior Notes
2019-12-16 12:00 ET
Bausch Health Resolves "Stock Drop" Litigation Initially Filed in October 2015
2019-11-13 13:00 ET
Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation
2019-11-11 11:55 ET
Bausch Health Companies Announces Participation in Upcoming Investor Conferences
2019-10-31 10:55 ET
Salix Announces Issuance of an Additional XIFAXAN® Patent
2019-10-30 10:55 ET
Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary
2019-10-28 10:55 ET
Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting
2019-10-21 11:58 ET
Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins

SEC forms

Show financial reports only

SEC form 10
2026-07-30 20:11 ET
Bausch Health Companies published news for 2026 q2
SEC form 8
2026-07-29 20:11 ET
Bausch Health Companies published news for 2026 q2
SEC form 8
2026-07-29 20:11 ET
Bausch Health Companies published news for 2026 q2
SEC form 10
2026-04-29 22:12 ET
Bausch Health Companies published news for 2026 q1
SEC form 8
2026-04-29 20:10 ET
Bausch Health Companies published news for 2026 q1
SEC form 8
2026-04-29 20:10 ET
Bausch Health Companies published news for 2026 q1
SEC form 10
2026-02-18 23:10 ET
Bausch Health Companies published news for 2025 q4
SEC form 8
2026-02-18 16:12 ET
Bausch Health Companies published news for 2025 q4
SEC form 8
2026-02-18 16:12 ET
Bausch Health Companies reported for 2025 q4
SEC form 8
2026-01-13 12:01 ET
Bausch Health Companies published news for 2025 q4
SEC form 8
2025-12-23 17:27 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-12-23 17:27 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-12-12 17:30 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-12-12 17:30 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-12-09 00:30 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-12-09 00:30 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-11-24 12:10 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-11-24 12:10 ET
Bausch Health Companies published news for 2025 q3
SEC form 10
2025-10-29 22:09 ET
Bausch Health Companies reported for 2025 q3
SEC form 8
2025-10-29 20:09 ET
Bausch Health Companies reported for 2025 q3
SEC form 8
2025-10-29 20:09 ET
Bausch Health Companies published news for 2025 q3
SEC form 8
2025-09-11 13:52 ET
Bausch Health Companies published news for 2025 q2
SEC form 10
2025-07-30 22:36 ET
Bausch Health Companies reported for 2025 q2
SEC form 8
2025-07-30 20:12 ET
Bausch Health Companies published news for 2025 q2
SEC form 8
2025-07-30 20:12 ET
Bausch Health Companies reported for 2025 q2
SEC form 8
2025-07-29 11:01 ET
Bausch Health Companies published news for 2025 q2
SEC form 8
2025-07-29 11:01 ET
Bausch Health Companies published news for 2025 q2
SEC form 8
2025-06-18 20:58 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-06-18 20:58 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-06-10 13:10 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-06-10 13:10 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-05-21 00:15 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-05-21 00:15 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-05-21 00:15 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-05-21 00:15 ET
Bausch Health Companies published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Bausch Health Companies reported for 2025 q1
SEC form 10
2025-04-30 22:03 ET
Bausch Health Companies reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Bausch Health Companies reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
Bausch Health Companies published news for 2025 q1
SEC form 8
2025-03-25 18:40 ET
Bausch Health Companies published news for 2024 q4
SEC form 8
2025-03-25 18:40 ET
Bausch Health Companies published news for 2024 q4
SEC form 8
2025-03-19 15:57 ET
Bausch Health Companies published news for 2024 q4
SEC form 8
2025-03-19 15:57 ET
Bausch Health Companies published news for 2024 q4
SEC form 8
2025-03-19 15:57 ET
Bausch Health Companies published news for 2024 q4
SEC form 10
2025-02-20 00:32 ET
Bausch Health Companies published news for 2024 q4
SEC form 10
2025-02-20 00:00 ET
Bausch Health Companies reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Bausch Health Companies reported for 2024 q4
SEC form 8
2025-02-19 00:00 ET
Bausch Health Companies published news for 2024 q4
SEC form 10
2024-10-31 00:00 ET
Bausch Health Companies reported for 2024 q3
SEC form 10
2024-10-30 19:13 ET
Bausch Health Companies reported for 2024 q3
SEC form 8
2024-10-30 16:16 ET
Bausch Health Companies published news for 2024 q3
SEC form 8
2024-10-30 16:16 ET
Bausch Health Companies reported for 2024 q3
SEC form 10
2024-08-01 16:45 ET
Bausch Health Companies published news for 2024 q2
SEC form 8
2024-08-01 07:07 ET
Bausch Health Companies reported for 2024 q2
SEC form 8
2024-08-01 07:07 ET
Bausch Health Companies published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Bausch Health Companies published news for 2024 q2
SEC form 10
2024-05-02 16:57 ET
Bausch Health Companies published news for 2024 q1
SEC form 8
2024-05-02 07:03 ET
Bausch Health Companies published news for 2024 q1
SEC form 8
2024-05-02 07:03 ET
Bausch Health Companies reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Bausch Health Companies published news for 2024 q1
SEC form 10
2024-02-22 17:04 ET
Bausch Health Companies published news for 2023 q4
SEC form 8
2024-02-22 07:04 ET
Bausch Health Companies reported for 2023 q4
SEC form 8
2024-02-22 07:04 ET
Bausch Health Companies published news for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Bausch Health Companies published news for 2023 q4
SEC form 10
2023-11-02 16:58 ET
Bausch Health Companies published news for 2023 q3
SEC form 8
2023-11-02 07:05 ET
Bausch Health Companies reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Bausch Health Companies published news for 2023 q3
SEC form 10
2023-08-03 16:46 ET
Bausch Health Companies published news for 2023 q2
SEC form 6
2023-08-03 07:05 ET
Bausch Health Companies reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Bausch Health Companies published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Bausch Health Companies published news for 2023 q2
SEC form 6
2023-07-07 08:07 ET
Bausch Health Companies published news for 2023 q2
SEC form 6
2023-07-07 08:06 ET
Bausch Health Companies published news for 2023 q2
SEC form 6
2023-06-30 09:17 ET
Bausch Health Companies published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Bausch Health Companies published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Bausch Health Companies published news for 2023 q1
SEC form 8
2023-02-23 00:00 ET
Bausch Health Companies reported for 2022 q4
SEC form 10
2023-02-23 00:00 ET
Bausch Health Companies reported for 2022 q4
SEC form 8
2022-11-03 00:00 ET
Bausch Health Companies reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Bausch Health Companies reported for 2022 q3
SEC form 8
2022-08-09 00:00 ET
Bausch Health Companies reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Bausch Health Companies reported for 2022 q2
SEC form 8
2022-05-10 00:00 ET
Bausch Health Companies reported for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Bausch Health Companies reported for 2022 q1
SEC form 8
2022-02-23 00:00 ET
Bausch Health Companies published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Bausch Health Companies published news for 2021 q4
SEC form 10
2021-11-02 00:00 ET
Bausch Health Companies published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Bausch Health Companies published news for 2021 q3
SEC form 10
2021-08-03 00:00 ET
Bausch Health Companies published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Bausch Health Companies published news for 2021 q2
SEC form 10
2021-05-04 00:00 ET
Bausch Health Companies published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Bausch Health Companies published news for 2021 q1